MetLife Inc stock: UBS Buy rating and $102 target signal upside potential

UBS just raised its price target on MetLife Inc stock to $102 while keeping a Buy rating, amid strong earnings and global expansion. This could matter for your portfolio if you're eyeing stable insurers with dividend appeal across U.S., Europe, or beyond. ISIN: US59156R1086

You're watching MetLife Inc (NYSE:MET, ISIN: US59156R1086) as it catches fresh attention from Wall Street, with UBS maintaining a Buy rating and lifting its price target to $102 from $98. This move underscores confidence in the insurer's ability to deliver amid economic shifts, especially after beating quarterly EPS expectations at $2.49 versus $2.34 forecast, with revenue surging 27.6% year-over-year to $52.44 billion. Whether you're a U.S. investor seeking dividends or building exposure in Europe, MetLife's global footprint makes it a stock worth evaluating now.

As of: 10.04.2026

By Elena Vargas, Senior Equity Analyst: MetLife Inc stands as a global insurance powerhouse navigating growth in diverse markets from the U.S. to Asia.

MetLife's Core Business: A Global Insurance Leader

MetLife Inc operates as one of the largest life insurers in the U.S. by assets, offering a broad range of life insurance, annuities, and related products to individuals and groups worldwide. You get exposure to six key segments: Group Benefits, Retirement and Income Solutions (RIS), Asia, Latin America, Europe/Middle East/Africa (EMEA), and MetLife Holdings, which handles run-off products. Group Benefits and RIS, both U.S.-focused, drive about 48% of the firm's adjusted earnings, providing stability through employer-sponsored plans and retirement offerings.

This structure lets MetLife balance domestic reliability with international growth opportunities. In Asia and Latin America, rising middle classes fuel demand for protection products, while EMEA taps into diverse markets. For you as an investor, this diversification reduces reliance on any single economy, making MetLife resilient during U.S. rate fluctuations or global slowdowns.

Recent earnings highlight this strength: the company reported EPS of $2.49, topping estimates, alongside robust revenue growth. Return on equity sits at 12.07%, with a net margin of 4.47%, signaling efficient operations in a capital-intensive industry. If you're building a portfolio for long-term income, MetLife's model aligns well with steady cash flows from premiums and investments.

Recent Catalysts Driving Momentum

UBS's recent upgrade of its price target to $102 reflects optimism about MetLife's trajectory, coming alongside a maintained Buy rating. The stock traded around $74.66 on the NYSE in U.S. dollars, with volume showing investor interest. This isn't isolated—MetLife Investment Management expanded its private fixed income portfolio, originating $26 billion in new transactions in 2025, bolstering its asset management capabilities.

These developments position MetLife to capitalize on higher yields in private credit, a trend benefiting insurers with strong balance sheets. For you, this means potential for improved investment income, which directly supports dividend payouts and growth initiatives. The company's global operations also shield it from regional downturns, as strength in Asia offsets any U.S. softness.

Should you buy now? If your strategy favors dividend aristocrats with growth upside, MetLife presents a compelling case, especially with Wall Street's average target implying significant potential from current levels. Trading on the NYSE in USD, it offers liquidity for global investors.

Analyst Views: Wall Street's Take on MetLife

Reputable firms show a generally positive outlook on MetLife, with UBS leading recent calls by maintaining Buy and raising its target to $102, a 4.08% increase from prior levels. This reflects analyst Michael Ward's view on the stock's potential, amid a consensus average target of $91.38 from 13 analysts, suggesting over 22% upside from around $74.88. The overall brokerage recommendation lands at 2.1 on a 1-5 scale, equating to Outperform status from 18 firms.

Other notables include Barclays' Overweight rating on April 8, 2026, though with a target trim to $89; Keefe, Bruyette & Woods' Outperform reinstatement at $87 on March 26; and TD Cowen's Buy at $88 on March 11. Morgan Stanley and Wells Fargo held Overweight stances earlier in the year, adjusting targets downward but staying constructive. These views, from established houses, highlight MetLife's competitive edge in insurance and asset management.

For you, this analyst consensus points to buy or hold territory rather than sell, with upside potential validated across multiple sources. If you're in Europe or elsewhere, note that NYSE:MET trades in USD, but ADRs or local access may apply—always check your broker. GuruFocus estimates a GF Value of $94.24, further supporting moderate-term optimism.

Why MetLife Matters to You as an Investor

MetLife delivers what many investors seek: reliable dividends backed by a fortress balance sheet and global diversification. U.S. investors appreciate the Group Benefits segment's steadiness, while Europeans might value EMEA exposure amid regional recovery plays. In a world of volatile tech stocks, MetLife offers defensive qualities with growth via emerging markets.

Recent portfolio expansion into private fixed income enhances yield potential, crucial as interest rates stabilize. You benefit from this as it supports earnings growth and share buybacks. Globally, MetLife's scale—among the top U.S. life insurers—gives it pricing power and cost efficiencies others lack.

What matters most right now? Strong earnings beats and analyst upgrades signal momentum, but the real draw is its role in diversified portfolios. If inflation concerns linger, insurers like MetLife thrive on floating-rate assets and premium growth.

Risks and Open Questions for MetLife Investors

No stock is without hurdles, and MetLife faces industry-wide pressures like rising claims from longevity trends and regulatory scrutiny in international markets. Interest rate sensitivity remains key: while higher rates boost investment income, sharp drops could squeeze margins. You should watch catastrophe losses, though MetLife's reinsurance mitigates this.

Competition from peers like Prudential or Allianz intensifies in Asia, where growth is hottest. Economic slowdowns could delay premium payments, especially in Latin America. Still, the company's 12.07% ROE shows resilience. Geopolitical tensions in EMEA add uncertainty—keep an eye on those regions.

What to watch next? Upcoming earnings for sustained beats, rate decisions from the Fed, and updates on private credit deployments. If you're global, currency fluctuations impact non-USD returns. Overall, risks are manageable for a firm of MetLife's stature.

Should You Buy MetLife Stock Now?

MetLife Inc combines dividend reliability with upside from analyst targets like UBS's $102 call, making it attractive if you prioritize insurers. Trading at around $74.66 on NYSE in USD, the stock offers entry below consensus averages, with strong fundamentals like revenue growth and portfolio expansion. For U.S., European, or global investors, it's relevant amid sector rotation toward financials.

Watch quarterly results, rate environments, and international growth for catalysts. Risks exist, but MetLife's track record suggests outperformance potential. Align it with your risk tolerance—defensive yet rewarding.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.